Table 2.
Clinical Signs Associated with EAE in (B10.S/SgMcdJ × SJL/J) F1 Hybrid and F2 Intercross Mice Injected with Ext-ENC-CFA and Int-ENC-CFA Emulsions
| Trait | F1 hybrid | P value | F2 intercross | P value |
|---|---|---|---|---|
| Incidence | ||||
| Ext-ENC-CFA | 24/24 (100)* | 248/251 (99) | ||
| Int-ENC-CFA | 11/50 (22) | <0.0001 | 37/494 (8) | <0.0001 |
| Onset | ||||
| Ext-ENC-CFA | 15.4 ± 1.4 | 15.4 ± 4.4 | ||
| Int-ENC-CFA | 23.6 ± 12.0 | 0.0021 | 21.1 ± 7.8 | <0.0001 |
| Severity | ||||
| Ext-ENC-CFA | 3.8 ± 0.4 | 3.1 ± 1.8 | ||
| Int-ENC-CFA | 2.3 ± 0.8 | <0.0001 | 2.3 ± 0.9 | 0.0086 |
| Weight loss† | ||||
| Ext-ENC-CFA | 4.6 ± 2.4 | 2.5 ± 2.5 | ||
| Int-ENC-CFA | 0.1 ± 2.6 | <0.0001 | 0.9 ± 1.6 | <0.0001 |
*Percent affected.
†The average weight loss was calculated using the total loss in grams for each animal from the baseline weight at injection to the peak of clinical disease.